Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$3.26

-0.09 (-2.69%)

06:03
08/10/18
08/10
06:03
08/10/18
06:03

Gemphire Therapeutics announces termination of Phase 2a trial of gemcabene

Gemphire Therapeutics announces that the Data and Safety Monitoring Board at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients with non-alcoholic fatty liver disease has recommended that the trial be terminated due to unanticipated problems. This pediatric NAFLD trial was initiated in early 2018. Patients were treated with gemcabene at a dose of 300 mg once daily. The primary endpoint is a measure of the change in serum alanine transaminase, an enzyme that serves as a biomarker of liver function, from baseline to 12 weeks, and secondary endpoints include, among others, change in hepatic steatosis (liver fat) as measured by non-invasive magnetic resonance imaging - proton density fat fraction. Data on the first three patients who underwent 12 weeks of treatment showed that all three experienced an increase in liver fat content, as measured by MRI-PDFF, and demonstrated increases in ALT. The increase in liver fat was deemed an unexpected problem by the trial investigator because it was an unexpected consistent pattern of worsening of the disease, rather than improvement, creating risk to the patients, which the investigator believed was likely due to the drug. Other patients currently enrolled in the trial have now been taken off gemcabene and early termination visits are being scheduled. The DSMB has recommended additional follow-up of the study subjects to gather additional safety data. The DSMB will provide Gemphire with a written report of their findings in the future once all the patient results have been collated and analyzed.

GEMP Gemphire Therapeutics
$3.26

-0.09 (-2.69%)

01/26/18
HCWC
01/26/18
NO CHANGE
Target $28
HCWC
Buy
Gemphire Therapeutics price target raised to $28 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Gemphire Therapeutics to $28 saying he sees a "catalyst-rich" 2018 for the company. The analyst says his confidence grows in the emerging multiple mechanisms of the compound as the gemcabene pipeline expands. He keeps a Buy rating on Gemphire Therapeutics.
05/16/18
RAJA
05/16/18
INITIATION
Target $22
RAJA
Outperform
Gemphire Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Gemphire Therapeutics with an Outperform and $22 price target saying its gemcabene offs a potentially differentiated profile in the dyslipidemia space, which should narrow the gap versus peers with successful data.
07/27/18
ROTH
07/27/18
NO CHANGE
Target $40
ROTH
Buy
Gemphire Therapeutics price target raised to $40 from $30 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Gemphire Therapeutics to $40 from $30 based on a positive forecast for the company's lead molecule in the pediatric NASH trial. In a research note to investors, Rahimi projects $415M peak sales for gemcabene for pediatric NASH in the U.S. in 2028 based on assumptions that include ~7.5M children with NAFLD among which 25% progress to NASH of which 12% have advanced NASH, as well as a U.S. launch in 2022 in 4% with peak market penetration of 55%. Rahimi, who has a Buy rating on Gemphire, sees top-line six-month histology results for the 24-week Phase 2a study in eight NASH patients with familial partial lipodystrophy in the fall, which will give clearer and early indications of gemcabene's effects on biopsy.
08/07/18
RAJA
08/07/18
DOWNGRADE
RAJA
Market Perform
Gemphire Therapeutics downgraded to Market Perform from Outperform at Raymond James

TODAY'S FREE FLY STORIES

EWZ

MSCI Brazil Index

$34.73

0.74 (2.18%)

06:55
08/15/18
08/15
06:55
08/15/18
06:55
Technical Analysis
MSCI Brazil Index: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$66.50

0.01 (0.02%)

06:54
08/15/18
08/15
06:54
08/15/18
06:54
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEFT

Euronet

$94.54

0.66 (0.70%)

06:54
08/15/18
08/15
06:54
08/15/18
06:54
Conference/Events
Euronet management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

  • 21

    Aug

  • 04

    Sep

  • 12

    Sep

JNK

SPDR Barclays High Yield Bond

$35.86

0.065 (0.18%)

06:53
08/15/18
08/15
06:53
08/15/18
06:53
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$22.78

0.025 (0.11%)

06:53
08/15/18
08/15
06:53
08/15/18
06:53
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIOD

Diodes

$37.81

0.07 (0.19%)

06:52
08/15/18
08/15
06:52
08/15/18
06:52
Conference/Events
Diodes management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.97

0.16 (0.19%)

06:52
08/15/18
08/15
06:52
08/15/18
06:52
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.50

0.155 (0.13%)

06:52
08/15/18
08/15
06:52
08/15/18
06:52
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$120.14

-0.32 (-0.27%)

06:51
08/15/18
08/15
06:51
08/15/18
06:51
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$14.17

0.075 (0.53%)

06:50
08/15/18
08/15
06:50
08/15/18
06:50
Technical Analysis
iShares Silver Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSOD

Cornerstone OnDemand

$52.59

0.48 (0.92%)

06:50
08/15/18
08/15
06:50
08/15/18
06:50
Conference/Events
Cornerstone OnDemand management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 04

    Sep

  • 06

    Sep

  • 07

    Sep

  • 12

    Sep

  • 12

    Sep

USLV

VelocityShares 3x Long Silver ETN

$7.31

0.12 (1.67%)

06:49
08/15/18
08/15
06:49
08/15/18
06:49
Technical Analysis
VelocityShares 3x Long Silver ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCMP

Cabot Microelectronics

$121.32

0.1 (0.08%)

06:49
08/15/18
08/15
06:49
08/15/18
06:49
Conference/Events
Cabot Microelectronics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 11

    Sep

IYR

DJ US Real Estate Index Fund

$81.16

0.44 (0.55%)

06:48
08/15/18
08/15
06:48
08/15/18
06:48
Technical Analysis
DJ US Real Estate Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLDR

Builders FirstSource

$16.86

0.85 (5.31%)

06:48
08/15/18
08/15
06:48
08/15/18
06:48
Conference/Events
Builders FirstSource management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 10

    Sep

  • 11

    Sep

  • 06

    Nov

BMS

Bemis

$49.51

0.12 (0.24%)

, BERY

Berry Global

$45.77

-0.07 (-0.15%)

06:48
08/15/18
08/15
06:48
08/15/18
06:48
Upgrade
Bemis, Berry Global, Graphic Packaging rating change  »

Bemis upgraded to Sector…

BMS

Bemis

$49.51

0.12 (0.24%)

BERY

Berry Global

$45.77

-0.07 (-0.15%)

GPK

Graphic Packaging

$14.30

0.19 (1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

IBB

iShares Nasdaq Biotechnology Index

$117.24

0.7 (0.60%)

06:48
08/15/18
08/15
06:48
08/15/18
06:48
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$118.97

0.8 (0.68%)

06:47
08/15/18
08/15
06:47
08/15/18
06:47
Periodicals
UPS reaches labor deal with aircraft mechanics, WSJ reports »

UPS has tentatively…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$25.69

-0.41 (-1.57%)

06:47
08/15/18
08/15
06:47
08/15/18
06:47
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$24.20

0.07 (0.29%)

06:46
08/15/18
08/15
06:46
08/15/18
06:46
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWG

iShares MSCI Germany

$29.59

(0.00%)

06:46
08/15/18
08/15
06:46
08/15/18
06:46
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$87.94

1.12 (1.29%)

06:46
08/15/18
08/15
06:46
08/15/18
06:46
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$42.76

0.265 (0.62%)

06:45
08/15/18
08/15
06:45
08/15/18
06:45
Technical Analysis
MSCI Emerging Markets Index: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:45
08/15/18
08/15
06:45
08/15/18
06:45
General news
Breaking General news story  »

Week of 8/10 MBA Mortgage…

EWW

iShares MSCI Mexico

$50.67

1.11 (2.24%)

06:44
08/15/18
08/15
06:44
08/15/18
06:44
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.